NorthStrive files patent application for muscle-wasting treatment EL-22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATED: NorthStrive Biosciences Files New U.S. Patent Application Covering EL-22 Formulations and Dosing for Treatment of Muscle-Wasting Conditions related to GLP-1 Use, Sarcopenia, Muscle Disuse Atr
April 28, 2026 4:01 PM EDTFiling seeks to extend EL-22 myostatin-engineered probiotic platform into pharmaceutical applications for muscle preservation in patients on GLP-1 receptor agonists and across multiple muscle-wasting indications
NEWPORT BEACH, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- NorthStrive Biosciences Inc. (NorthStrive or the Company), a wholly owned subsidiary of PMGC Holdings Inc. (Nasdaq: ELAB) (PMGC), today announced the filing of a new U.S. patent application covering pharmaceutical formulations and dosing regimens of EL-22, the Companys proprietary myostatin-engineered probiotic, for the treatment of muscle-wasting conditions, including muscle loss associated with GLP-1 receptor agonist therapy, sarcopenia, muscle... More
